Showing results (1-10 of 146) with videos related to
Sort By:
Pageof 15
Journal of Hematology & Oncology|June 21, 2017
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytesMichela Sica, Tommaso Rondelli, Patrizia Ricci, et al.Haematologica|October 30, 2020
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuriaAntonio M Risitano, Austin G Kulasekararaj, Jong Wook Lee, et al.Blood|July 27, 2021
Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumabAustin G Kulasekararaj, Antonio M Risitano, Jaroslaw P Maciejewski, et al.British Journal of Haematology|December 2, 2010
Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are goingAntonio M RisitanoImmunobiology|September 12, 2012
Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disordersAntonio M RisitanoHematology/Oncology Clinics of North America|June 5, 2015
Current and future pharmacologic complement inhibitorsAntonio M RisitanoCurrent Opinion in Hematology|December 7, 2011
Immunosuppressive therapies in the management of acquired immune-mediated marrow failuresAntonio M RisitanoAdvances in Experimental Medicine and Biology|February 14, 2013
Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategiesAntonio M RisitanoTranslational Medicine @ Unisa|April 30, 2014
Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are GoingAntonio M RisitanoPageof 15